Formic Acid

Formic Acid

SCHEMBL7216484

CC(C)(C)OC(=O)NC1CCNCC1.O=CO

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.48
EPHX1 P07099 3/20 0.47
CTSK P43235 2/20 0.44
GAA P10253 2/20 0.43
POLB P06746 1/20 0.43
KDM1A O60341 1/20 0.42
MAOB P27338 1/20 0.42
EPHX2 P34913 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
KCNA3 P22001 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
GNAI3 P08754 1/20 0.38
GNAO1 P09471 1/20 0.38
GNAI1 P63096 1/20 0.38
CYP2C9 P11712 1/20 0.38
HSD11B1 P28845 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL56856 0.93 EPHX1 (0.53) BTKEPHX1CTSKGAAPOLB
Water SCHEMBL27795194 0.92 EPHX1 (0.52) BTKEPHX1CTSKGAAPOLB
Ammonia Solution, Strong SCHEMBL15021680 0.92 EPHX1 (0.52) BTKEPHX1CTSKGAAPOLB
Hydrochloric Acid SCHEMBL4158527 0.92 EPHX1 (0.52) BTKEPHX1CTSKGAAPOLB
Alcohol SCHEMBL28064671 0.87 BTK (0.48) BTKEPHX1CTSKGAAPOLB
Acetic Acid Methyl Ester SCHEMBL8483324 0.87 BTK (0.48) BTKEPHX1CTSKGAAPOLB
SCHEMBL555051 0.87 BTK (0.55) BTKEPHX1CTSKGAAPOLB
SCHEMBL14209134 0.87 BTK (0.55) BTKEPHX1CTSKGAAPOLB
SCHEMBL14209088 0.87 BTK (0.55) BTKEPHX1CTSKGAAPOLB
Methyl Carbamate SCHEMBL28171804 0.86 BTK (0.47) BTKEPHX1CTSKGAAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed